SR One Capital Management Discloses 8.0% Stake in Odyssey Therapeutics Post-IPO
ODTX is trading near its 52-week low of $16.405 (6.0% above the low).
Summary
SR One Capital Management has disclosed an 8.0% ownership stake in Odyssey Therapeutics, primarily from pre-IPO investments and IPO purchases, signaling strong institutional confidence in the newly public company.
Key Events · Ownership and Investor Activity · ODTX
-
Significant Institutional Stake
SR One Capital Management and its affiliates disclosed an 8.0% beneficial ownership stake, totaling 3,794,883 shares, in Odyssey Therapeutics.
-
Post-IPO Investment Confirmation
The stake is a result of pre-IPO preferred stock conversions and purchases during the company's recent initial public offering, which was priced at $18.00 per share.
-
Lock-Up Agreement in Place
The reporting persons are subject to a 180-day lock-up agreement, restricting sales of shares post-IPO, indicating a long-term investment horizon.
Analysis · ODTX · Life Sciences
This Schedule 13D filing reveals that SR One Capital Management and its affiliates, including Simeon George, M.D., hold an 8.0% beneficial ownership stake in Odyssey Therapeutics. This significant position, valued at approximately $68.3 million based on the IPO price, primarily stems from the conversion of pre-IPO preferred stock and additional purchases during the recent initial public offering. The disclosure confirms substantial institutional backing for the newly public company.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ODTX was trading at $17.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $823.1M. The 52-week trading range was $16.41 to $18.06. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.